Sonnet BioTherapeutics Holdings, Inc. (SONN)

NASDAQ: SONN · Real-Time Price · USD
1.310
0.00 (0.00%)
At close: Mar 28, 2025, 4:00 PM
1.330
+0.020 (1.53%)
After-hours: Mar 28, 2025, 7:39 PM EDT
0.00%
Market Cap 4.02M
Revenue (ttm) 1,000,000
Net Income (ttm) -9.43M
Shares Out 3.07M
EPS (ttm) -9.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 68,849
Open 1.330
Previous Close 1.310
Day's Range 1.240 - 1.320
52-Week Range 1.220 - 16.800
Beta 1.01
Analysts Strong Buy
Price Target 38.00 (+2,800.76%)
Earnings Date May 13, 2025

About SONN

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck c... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Pankaj Mohan
Employees 13
Stock Exchange NASDAQ
Ticker Symbol SONN
Full Company Profile

Financial Performance

In 2024, SONN's revenue was $18,626, a decrease of -87.40% compared to the previous year's $147,805. Losses were -$7.44 million, -60.51% less than in 2023.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for SONN stock is "Strong Buy." The 12-month stock price forecast is $38.0, which is an increase of 2,800.76% from the latest price.

Price Target
$38.0
(2,800.76% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas

SON-1010 is being studied as a combination therapy with trabectedin (Yondelis ®), the first FDA-approved treatment for two types of advanced soft tissue sarcoma after failure of standard chemotherapy...

4 days ago - GlobeNewsWire

Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein

Company advancing development of its modified version of Interleukin-18 (IL-18 Binding Protein Resistant or IL-18 BPR) that exhibits wild-type binding to the IL-18 receptor (IL-18Rc), coupled with un...

11 days ago - GlobeNewsWire

Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors

Poster presented at the 2025 AACR:IO Conference Company's novel platform that delivers either mono- or bifunctional immunomodulators linked to a Fully-Human, Albumin Binding scFv domain (F H AB ®)  p...

4 weeks ago - GlobeNewsWire

Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates

Building on proven targeting of the F H AB domain, Sonnet's ADC platform offers flexible payload capacity and controllable drug-antibody ratios (DAR)

5 weeks ago - GlobeNewsWire

Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference

PRINCETON, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drug...

5 weeks ago - GlobeNewsWire

Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer

PRINCETON, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs...

6 weeks ago - GlobeNewsWire

Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update

Completion of SON-1010 (IL12-F H AB) monotherapy dose escalation in Phase 1 SB101 trial; Stable disease (SD) at four months post-initiation of dosing was seen in 48% evaluable monotherapy patients, an...

6 weeks ago - GlobeNewsWire

Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology

European Patent Office (EPO) grants EU Patent No. EP3583125 B1 covering the Company's Fully Human Albumin Binding (FHAB®) domain fusion proteins

2 months ago - GlobeNewsWire

Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Live webcast on Wednesday, January 29 th at 2:40 PM ET PRINCETON, NJ, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-sta...

2 months ago - GlobeNewsWire

Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas

SON-1010, after receipt of data suggesting clinical benefit when administered as a monotherapy in patients with advanced solid tumors, enters combination evaluation with trabectedin (Yondelis ®) with...

2 months ago - GlobeNewsWire

Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment

PRINCETON, NJ, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs,...

3 months ago - GlobeNewsWire

Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Continued progress with both clinical trials of lead program, SON-1010, for solid tumors and Platinum-Resistant Ovarian Cancer (PROC)

3 months ago - GlobeNewsWire

Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

PRINCETON, NJ, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the "Company" or "Sonnet") (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, ...

3 months ago - GlobeNewsWire

Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial

The maximum tolerated dose (MTD) of SON-1010 was set at 1200 ng/kg, without dose-limiting toxicity or evidence of cytokine release syndrome at any dose level

3 months ago - GlobeNewsWire

Sonnet BioTherapeutics Announces Publication Detailing the Discovery and Development of SON-1010, an Albumin-Binding IL-12 Fusion Protein, Demonstrating Its Mechanism of Action

Pankaj Mohan, CEO of Sonnet discusses what this publication means in a Virtual Investor “What This Means” segment; access here

4 months ago - GlobeNewsWire

Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment

Drs. Pankaj Mohan, CEO of Sonnet, and John Cini, CSO of Sonnet, discuss the Company's recent issuance of a U.S. patent covering a variant of IL-18 incorporated into two novel immunotherapeutic drug ca...

4 months ago - GlobeNewsWire

Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules

PRINCETON, NJ, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the "Company" or "Sonnet”) (NASDAQ: SONN), a clinical-stage company developing innovative targeted immunotherape...

5 months ago - GlobeNewsWire

Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates

Both novel bifunctional (SON-1411) and monofunctional (SON-1400) fusion proteins exhibit wild-type binding to the IL-18 receptor (IL-18Rc), coupled with undetectable binding to the inhibitory IL-18 bi...

5 months ago - GlobeNewsWire

Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq

PRINCETON, NJ, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs,...

5 months ago - GlobeNewsWire

Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India

Sonnet to receive $1.0 million in upfront payment and up to an additional $1.0 million in milestone payments with a royalty in the low double digits on net sales, less certain expenses, in the India m...

6 months ago - GlobeNewsWire

Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs

PRINCETON, NJ, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs,...

6 months ago - GlobeNewsWire

Sonnet BioTherapeutics Announces Launch of CEO Corner Platform

CEO Corner segments to include additional discussion related to press releases, events, corporate updates and pipeline progress

6 months ago - GlobeNewsWire

Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split

PRINCETON, N.J., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (“Sonnet” or the “Company”) (NASDAQ: SONN), a biopharmaceutical company developing innovative targeted biologi...

6 months ago - GlobeNewsWire

Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors

SON-1010 is a targeted immune activation cancer therapy designed to turn ‘cold' tumors ‘hot' Topline safety data of SB101 Phase 1 study expected by Q4 2024 PRINCETON, NJ, Sept. 18, 2024 (GLOBE NEWSWIR...

6 months ago - GlobeNewsWire